JACKSON, MI - July 09, 2026 - PRESSADVANTAGE - Nu-Ice Dry Ice Blasting™ has announced continued emphasis on compact ...

Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of buzzy data drops, practice-changing posters and ...

ASCO didn’t always look like a massive cityscape of pharma booths with a strong advertising presence. Historically, the heavy focus was on medical affairs, given the conference is mainly attended by ...

RASolute 302 showed daraxonrasib reduced mortality risk by 60% versus chemotherapy in previously treated metastatic PDAC, with median OS 13.2 versus 6.7 months. OPTIMA found Prosigna-defined low-risk ...

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens. At the 2026 annual meeting of the American Society of ...

While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hopes to do the same ...

Three phase III trial results presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago this weekend delivered what oncologists are already calling the most consequential ...

Jason Gerberry, BofA Securities senior large-cap pharma analyst, joins 'Squawk Box' to discuss the 2026 ASCO Annual Meeting, what to expect from the conference, latest cancer treatment announcements, ...

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...